New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review)
- Authors:
- Antonio Stigliano
- Lidia Cerquetti
- Pina Lardo
- Elisa Petrangeli
- Vincenzo Toscano
-
Affiliations: Endocrinology, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy, CNR, Institute of Molecular Biology and Pathology, Sapienza University of Rome, 00161 Rome, Italy - Published online on: February 7, 2017 https://doi.org/10.3892/or.2017.5427
- Pages: 1301-1311
This article is mentioned in:
Abstract
Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, Giordano TJ and Hammer GD: Adrenocortical carcinoma. Endocr Rev. 35:282–326. 2014. View Article : Google Scholar : PubMed/NCBI | |
Barlaskar FM and Hammer GD: The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord. 8:343–348. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ragazzon B, Assié G and Bertherat J: Transcriptome analysis of adrenocortical cancers: From molecular classification to the identification of new treatments. Endocr Relat Cancer. 18:R15–R27. 2011.PubMed/NCBI | |
Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, et al: Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 46:607–612. 2014. View Article : Google Scholar : PubMed/NCBI | |
Assié G, Jouinot A and Bertherat J: The ‘omics’ of adrenocortical tumours for personalized medicine. Nat Rev Endocrinol. 10:215–228. 2014. View Article : Google Scholar : PubMed/NCBI | |
Fassnacht M, Libé R, Kroiss M and Allolio B: Adrenocortical carcinoma: A clinician's update. Nat Rev Endocrinol. 7:323–335. 2011. View Article : Google Scholar : PubMed/NCBI | |
Fassnacht M, Kenn W and Allolio B: Adrenal tumors: How to establish malignancy? J Endocrinol Invest. 27:387–399. 2004. View Article : Google Scholar : PubMed/NCBI | |
Tauchmanovà L, Colao A, Marzano LA, Sparano L, Camera L, Rossi A, Palmieri G, Marzano E, Salvatore M, Pettinato G, et al: Andrenocortical carcinomas: Twelve-year prospective experience. World J Surg. 28:896–903. 2004. View Article : Google Scholar : PubMed/NCBI | |
Arlt W, Biehl M, Taylor AE, Hahner S, Libé R, Hughes BA, Schneider P, Smith DJ, Stiekema H, Krone N, et al: Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 96:3775–3784. 2011. View Article : Google Scholar : PubMed/NCBI | |
Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, Reimondo G, Pia A, Toscano V, Zini M, et al: Italian Association of Clinical Endocrinologists: AME position statement on adrenal incidentaloma. Eur J Endocrinol. 164:851–870. 2011. View Article : Google Scholar : PubMed/NCBI | |
Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, Halpern EF, Mueller PR, Hahn PF and Boland GW: Distinguishing benign from malignant adrenal masses: Multi-detector row CT protocol with 10-minute delay. Radiology. 238:578–585. 2006. View Article : Google Scholar : PubMed/NCBI | |
Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, Allolio B and Fassnacht M: German ACC Study Group: Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: Analysis of the German ACC registry. Eur J Endocrinol. 172:415–422. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wong KK, Arabi M, Zerizer I, Al-Nahhas A, Rubello D and Gross MD: Role of positron emission tomography/computed tomography in adrenal and neuroendocrine tumors: Fluorodeoxyglucose and nonfluorodeoxyglucose tracers. Nucl Med Commun. 32:764–781. 2011. View Article : Google Scholar : PubMed/NCBI | |
Hennings J, Lindhe O, Bergström M, Långström B, Sundin A and Hellman P: [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab. 91:1410–1414. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Bock S, Verburg FA, Knoedler P, Lang K, Reiners C, Buck AK, et al: Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. J Clin Endocrinol Metab. 98:1508–1518. 2013. View Article : Google Scholar : PubMed/NCBI | |
Delellis RA, Lloyd RV and Heitz PU: Pathology and Genetics of Tumours of Endocrine OrgansEble JN, Sauter G, Epstein JE and Sesterhenn IA: IARC; Lyon: 2004 | |
MacFarlane DA: Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl. 23:155–186. 1958.PubMed/NCBI | |
Sullivan M, Boileau M and Hodges CV: Adrenal cortical carcinoma. J Urol. 120:660–665. 1978.PubMed/NCBI | |
Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S and Allolio B: German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification. Cancer. 115:243–250. 2009. View Article : Google Scholar : PubMed/NCBI | |
Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, Shariat SF, Guazzoni G, Montorsi F, et al: The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer. 46:713–719. 2010. View Article : Google Scholar : PubMed/NCBI | |
Creemers SG, Hofland LJ, Korpershoek E, Franssen GJ, van Kemenade FJ, de Herder WW and Feelders RA: Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Endocr Relat Cancer. 23:R43–R69. 2016.PubMed/NCBI | |
Stigliano A, Chiodini I, Giordano R, Faggiano A, Canu L, Casa S Della, Loli P, Luconi M, Mantero F and Terzolo M: Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE). J Endocrinol Invest. 39:103–121. 2016. View Article : Google Scholar : PubMed/NCBI | |
Crucitti F, Bellantone R, Ferrante A, Boscherini M and Crucitti P: The ACC Italian Registry Study Group: The Italian Registry for Adrenal Cortical Carcinoma: Analysis of a multiinstitutional series of 129 patients. Surgery. 119:161–170. 1996. View Article : Google Scholar : PubMed/NCBI | |
Donatini G, Caiazzo R, Do Cao C, Aubert S, Zerrweck C, El-Kathib Z, Gauthier T, Leteurtre E, Wemeau JL, Vantyghem MC, et al: Long-term survival after adrenalectomy for stage I/II adrenocortical carcinoma (ACC): A retrospective comparative cohort study of laparoscopic versus open approach. Ann Surg Oncol. 21:284–291. 2014. View Article : Google Scholar : PubMed/NCBI | |
Vaughan ED Jr.: Diseases of the adrenal gland. Med Clin North Am. 88:443–466. 2004. View Article : Google Scholar : PubMed/NCBI | |
Huang H and Fojo T: Adjuvant mitotane for adrenocortical cancer - a recurring controversy. J Clin Endocrinol Metab. 93:3730–3732. 2008. View Article : Google Scholar : PubMed/NCBI | |
Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF and Proye C: Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 25:891–897. 2001. View Article : Google Scholar : PubMed/NCBI | |
Lombardi CP, Raffaelli M, De Crea C, Boniardi M, De Toma G, Marzano LA, Miccoli P, Minni F, Morino M, Pelizzo MR, et al: Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: Results of a multiinstitutional Italian survey. Surgery. 152:1158–1164. 2012. View Article : Google Scholar : PubMed/NCBI | |
Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, Berruti A and Terzolo M: Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 57:873–878. 2010. View Article : Google Scholar : PubMed/NCBI | |
Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, Behrend M, Allolio B and Fassnacht M: German ACC study group: Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 255:363–369. 2012. View Article : Google Scholar : PubMed/NCBI | |
Gaujoux S and Brennan MF: Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 152:123–132. 2012. View Article : Google Scholar : PubMed/NCBI | |
Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T and Schrump DS: Pulmonary resection for metastatic adrenocortical carcinoma: The National Cancer Institute experience. Ann Thorac Surg. 92:1195–1200. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, Wood BJ, Kammula US, Fojo T, et al: Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 18:1972–1979. 2011. View Article : Google Scholar : PubMed/NCBI | |
Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, Cordon-Cardo C, Jaques DP and Brennan MF: Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol. 20:941–950. 2002. View Article : Google Scholar : PubMed/NCBI | |
Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, Fojo T, Schrump DS and Avital I: Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 105:709–713. 2012. View Article : Google Scholar : PubMed/NCBI | |
Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J, Willenberg HS, Beuschlein F, Fottner C, et al: German Adrenocortical Carcinoma Study Group: The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 98:181–191. 2013. View Article : Google Scholar : PubMed/NCBI | |
Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M and Worden FP: Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer. 12:667–680. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lin CW, Chang YH and Pu HF: Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology. 298:14–23. 2012. View Article : Google Scholar : PubMed/NCBI | |
Lehmann TP, Wrzesiński T and Jagodziński PP: The effect of mitotane on viability, steroidogenesis and gene expression in NCI-H295R adrenocortical cells. Mol Med Rep. 7:893–900. 2013.PubMed/NCBI | |
van Slooten H, Moolenaar AJ, van Seters AP and Smeenk D: The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 20:47–53. 1984. View Article : Google Scholar : PubMed/NCBI | |
Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, et al: Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab. 96:1844–1851. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid B, Leboulleux S, Mantero F, Haak HR, et al: Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 98:4759–4767. 2013. View Article : Google Scholar : PubMed/NCBI | |
Fassnacht M and Allolio B: Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 23:273–289. 2009. View Article : Google Scholar : PubMed/NCBI | |
Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, deVries JH, Zaggia B, et al: Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 169:263–270. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mauclère-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, Deandreis D, Drouard L, Tabarin A, Chanson P, et al: High-dose mitotane strategy in adrenocortical carcinoma: Prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Eur J Endocrinol. 166:261–268. 2012. View Article : Google Scholar : PubMed/NCBI | |
van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J and Gelderblom H: Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol. 164:621–626. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kroiss M, Quinkler M, Lutz WK, Allolio B and Fassnacht M: Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 75:585–591. 2011. View Article : Google Scholar : PubMed/NCBI | |
Haak HR, Hermans J, van De Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ and Krans HM: Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer. 69:947–951. 1994. View Article : Google Scholar : PubMed/NCBI | |
Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G and Schlumberger M: Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 92:1385–1392. 2001. View Article : Google Scholar : PubMed/NCBI | |
Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, et al: Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 356:2372–2380. 2007. View Article : Google Scholar : PubMed/NCBI | |
Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M and Pentheroudakis G: ESMO Guidelines Working Group: Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 23 Suppl 7:vii131–vii138. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL and Fojo AT: Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab. 73:18–29. 1991. View Article : Google Scholar : PubMed/NCBI | |
Berruti A, Terzolo M, Sperone P, Pia A, Casa S Della, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, et al: Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: A large prospective phase II trial. Endocr Relat Cancer. 12:657–666. 2005. View Article : Google Scholar : PubMed/NCBI | |
Khan TS, Imam H, Juhlin C, Skogseid B, Gröndal S, Tibblin S, Wilander E, Oberg K and Eriksson B: Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use. Ann Oncol. 11:1281–1287. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E and Harker WG: Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study. J Clin Oncol. 11:161–165. 1993. View Article : Google Scholar : PubMed/NCBI | |
Schteingart DE: Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 33:1197–1200. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux AF, Nakib I and Schlumberger M: Réseau Comète: Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer. 78:546–549. 1998. View Article : Google Scholar : PubMed/NCBI | |
Burgess MA, Legha SS and Sellin RV: Chemotherapy with cisplatinum and etoposide (UP16) for patients with advanced adrenal cortical carcinoma (ACC). Proc ASCO. 12:1881993. | |
Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH and Crawford ED: Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group Study. Cancer. 88:1159–1165. 2000. View Article : Google Scholar : PubMed/NCBI | |
Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, et al: FIRM-ACT Study Group: Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 366:2189–2197. 2012. View Article : Google Scholar : PubMed/NCBI | |
Germano A, Rapa I, Volante M, Lo Buono N, Carturan S, Berruti A, Terzolo M and Papotti M: Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Mol Cell Endocrinol. 382:1–7. 2014. View Article : Google Scholar : PubMed/NCBI | |
Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M and Allolio B: Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 91:4501–4504. 2006. View Article : Google Scholar : PubMed/NCBI | |
Sabolch A, Feng M, Griffith K, Hammer G, Doherty G and Ben-Josef E: Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 80:1477–1484. 2011. View Article : Google Scholar : PubMed/NCBI | |
Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, et al: A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 98:192–197. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola D, Piergrossi P, Brunetti E, et al: Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr Relat Cancer. 15:623–634. 2008. View Article : Google Scholar : PubMed/NCBI | |
Cerquetti L, Sampaoli C, Amendola D, Bucci B, Misiti S, Raza G, De Paula U, Marchese R, Brunetti E, Toscano V, et al: Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int J Oncol. 37:493–501. 2010.PubMed/NCBI | |
Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, Kenn W, Hahner S, Allolio B and Flentje M: Radiotherapy in adrenocortical carcinoma. Cancer. 115:2816–2823. 2009. View Article : Google Scholar : PubMed/NCBI | |
De Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E and Bertherat J: Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 27:1108–1115. 2009. View Article : Google Scholar : PubMed/NCBI | |
Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E and Hammer GD: Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab. 94:204–212. 2009. View Article : Google Scholar : PubMed/NCBI | |
Tacon LJ, Prichard RS, Soon PSH, Robinson BG, Clifton-Bligh RJ and Sidhu SB: Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist. 16:36–48. 2011. View Article : Google Scholar : PubMed/NCBI | |
Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, De Bono JS, Gualberto A and Hammer GD: Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 65:765–773. 2010. View Article : Google Scholar : PubMed/NCBI | |
Carden CP, Frentzas S and Langham M: Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol. 27:35442009. | |
Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, et al: Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. Lancet Oncol. 16:426–435. 2015. View Article : Google Scholar : PubMed/NCBI | |
Doghman M, El Wakil A, Cardinaudet B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP and Lalli E: Regulation of IGF-mTOR signalling by miRNA in childhood adrenocortical tumors. Cancer Res. 70:4666–4675. 2010. View Article : Google Scholar : PubMed/NCBI | |
De Martino MC, van Koetsveld PM, Pivonello R and Hofland LJ: Role of the mTOR pathway in normal and tumoral adrenal cells. Neuroendocrinology. 92 Suppl 1:28–34. 2010. View Article : Google Scholar : PubMed/NCBI | |
Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle LA, Heilbrun LK, et al: Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 17:6052–6060. 2011. View Article : Google Scholar : PubMed/NCBI | |
Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K and Hammer GD: The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: A multi-institutional NCI-sponsored trial. Horm Cancer. 5:232–239. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B and Fassnacht M: Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 162:349–356. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chacón R, Tossen G, Loria FS and Chacón M: CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol. 23:1579–1580. 2005. View Article : Google Scholar : PubMed/NCBI | |
Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pöllinger A, Laubner K, Strasburger CJ, Hahner S, Müller HH, et al: Sunitinib in refractory adrenocortical carcinoma: A phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 97:3495–3503. 2012. View Article : Google Scholar : PubMed/NCBI | |
Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, et al: Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 15:7061–7068. 2009. View Article : Google Scholar : PubMed/NCBI | |
Butler C, Butler WM and Rizvi AA: Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract. 16:441–445. 2010. View Article : Google Scholar : PubMed/NCBI | |
Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, Volante M, Daffara F, Generali D, et al: Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 166:451–458. 2012. View Article : Google Scholar : PubMed/NCBI | |
Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE, Kim H, Kim JH, Bang SM, Kim JS and Lee JS: Metastatic adrenocortical carcinoma treated with sunitinib: A case report. Jpn J Clin Oncol. 39:183–185. 2009. View Article : Google Scholar : PubMed/NCBI | |
Gangadhar TC, Cohen EEW, Wu K, Janisch L, Geary D, Kocherginsky M, House LK, Ramirez J, Undevia SD, Maitland ML, et al: Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 17:1956–1963. 2011. View Article : Google Scholar : PubMed/NCBI | |
Xu YZ, Zhu Y, Shen ZJ, Sheng JY, He HC, Ma G, Qi YC, Zhao JP, Wu YX, Rui WB, et al: Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: Potential for therapy. Endocrine. 40:445–451. 2011. View Article : Google Scholar : PubMed/NCBI | |
Assié G, Guillaud-Bataille M, Ragazzon B, Bertagna X, Bertherat J and Clauser E: The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends Endocrinol Metab. 21:325–334. 2010. View Article : Google Scholar : PubMed/NCBI | |
Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, Allolio B and Fassnacht M: Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 93:2057–2062. 2008. View Article : Google Scholar : PubMed/NCBI | |
Samnotra V, Vassilopoulou-Sellin R and Fojo AT: A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol. 27:155272007. | |
Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, et al: Israel Glivec in Solid Tumors Study Group: The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 13:535–540. 2006. View Article : Google Scholar : PubMed/NCBI | |
Adam P, Hahner S, Hartmann M, Heinrich B, Quinkler M, Willenberg HS, Saeger W, Sbiera S, Schmull S, Voelker HU, et al: Epidermal growth factor receptor in adrenocortical tumors: Analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol. 23:1596–1604. 2010. View Article : Google Scholar : PubMed/NCBI | |
Gagliano T, Gentilin E, Benfini K, Di Pasquale C, Tassinari M, Falletta S, Feo C, Tagliati F, Uberti ED and Zatelli MC: Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. Endocrine. 47:943–951. 2014. View Article : Google Scholar : PubMed/NCBI | |
Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, et al: A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer. 94:2333–2343. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kahn CR, Chen L and Cohen SE: Unraveling the mechanism of action of thiazolidinediones. J Clin Invest. 106:1305–1307. 2000. View Article : Google Scholar : PubMed/NCBI | |
Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M and Beuschlein F: German and Austrian Adrenal Network: Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab. 90:3886–3896. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M and Mannelli M: Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab. 90:1332–1339. 2005. View Article : Google Scholar : PubMed/NCBI | |
Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, et al: Rosiglitazone impairs proliferation of human adrenocortical cancer: Preclinical study in a xenograft mouse model. Endocr Relat Cancer. 17:169–177. 2010. View Article : Google Scholar : PubMed/NCBI | |
Cerquetti L, Sampaoli C, Amendola D, Bucci B, Masuelli L, Marchese R, Misiti S, De Venanzi A, Poggi M, Toscano V, et al: Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp Cell Res. 317:1397–1410. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM, René-Corail F, Jullian E, Gicquel C, Bertagna X, et al: Mutations of β-catenin in adrenocortical tumors: Activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65:7622–7627. 2005.PubMed/NCBI | |
Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libé R, Chokri I, Audebourg A, Royer B, Sbiera S, et al: β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res. 17:328–336. 2011. View Article : Google Scholar : PubMed/NCBI | |
Doghman M, Cazareth J and Lalli E: The T cell factor/β-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab. 93:3222–3225. 2008. View Article : Google Scholar : PubMed/NCBI | |
Gaujoux S, Hantel C, Launay P, Bonnet S, Perlemoine K, Lefèvre L, Guillaud-Bataille M, Beuschlein F, Tissier F, Bertherat J, et al: Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PLoS One. 8:e557432013. View Article : Google Scholar : PubMed/NCBI | |
Demeure MJ, Bussey KJ and Kirschner LS: Targeted therapies for adrenocortical carcinoma: IGF and beyond. Horm Cancer. 2:385–392. 2011. View Article : Google Scholar : PubMed/NCBI | |
Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, et al: High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 95:E161–E171. 2010. View Article : Google Scholar : PubMed/NCBI | |
Duregon E, Volante M, Giorcelli J, Terzolo M, Lalli E and Papotti M: Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: A validation study focusing on clinical and pathologic correlates. Hum Pathol. 44:822–828. 2013. View Article : Google Scholar : PubMed/NCBI | |
Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, Virolle V, Barbry P, Zambetti GP, Figueiredo BC, et al: Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol. 21:2968–2987. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ehrlund A, Jonsson P, Vedin LL, Williams C, Gustafsson JÅ and Treuter E: Knockdown of SF-1 and RNF31 affects components of steroidogenesis, TGFβ, and Wnt/β-catenin signaling in adrenocortical carcinoma cells. PLoS One. 7:e320802012. View Article : Google Scholar : PubMed/NCBI | |
Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P and Lalli E: Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J Clin Endocrinol Metab. 94:2178–2183. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chuman Y, Zhan Z and Fojo T: Construction of gene therapy vectors targeting adrenocortical cells: Enhancement of activity and specificity with agents modulating the cyclic adenosine 3′,5′-monophosphate pathway. J Clin Endocrinol Metab. 85:253–262. 2000. View Article : Google Scholar : PubMed/NCBI | |
Sbiera S, Wortmann S and Fassnacht M: Dendritic cell based immunotherapy - a promising therapeutic approach for endocrine malignancies. Horm Metab Res. 40:89–98. 2008. View Article : Google Scholar : PubMed/NCBI | |
Papewalis C, Fassnacht M, Willenberg HS, Domberg J, Fenk R, Rohr UP, Schinner S, Bornstein SR, Scherbaum WA and Schott M: Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma. Clin Endocrinol (Oxf). 65:215–222. 2006. View Article : Google Scholar : PubMed/NCBI | |
van Koetsveld PM, Vitale G, Feelders RA, Waaijers M, Sprij-Mooij DM, De Krijger RR, Speel EJ, Hofland J, Lamberts SW, De Herder WW, et al: Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr Relat Cancer. 20:443–454. 2013. View Article : Google Scholar : PubMed/NCBI | |
Liu-Chittenden Y, Jain M, Kumar P, Patel D, Aufforth R, Neychev V, Sadowski S, Gara SK, Joshi BH, Cottle-Delisle C, et al: Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma. Cancer Med. 4:1060–1068. 2015. View Article : Google Scholar : PubMed/NCBI | |
Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI | |
Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, Yeh MW, Wong SG, Clifton-Bligh RJ, Robinson BG, et al: miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res. 15:7684–7692. 2009. View Article : Google Scholar : PubMed/NCBI | |
Glover AR, Zhao JT, Gill AJ, Weiss J, Mugridge N, Kim E, Feeney AL, Ip JC, Reid G, Clarke S, et al: MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. Oncotarget. 6:36675–36688. 2015.PubMed/NCBI | |
De Cremoux P, Rosenberg D, Goussard J, Brémont-Weil C, Tissier F, Tran-Perennou C, Groussin L, Bertagna X, Bertherat J and Raffin-Sanson ML: Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease. Endocr Relat Cancer. 15:465–474. 2008. View Article : Google Scholar : PubMed/NCBI | |
Barzon L, Masi G, Pacenti M, Trevisan M, Fallo F, Remo A, Martignoni G, Montanaro D, Pezzi V and Palù G: Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch. 452:181–191. 2008. View Article : Google Scholar : PubMed/NCBI | |
Montanaro D, Maggiolini M, Recchia AG, Sirianni R, Aquila S, Barzon L, Fallo F, Andò S and Pezzi V: Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation. J Mol Endocrinol. 35:245–256. 2005. View Article : Google Scholar : PubMed/NCBI | |
Sirianni R, Zolea F, Chimento A, Ruggiero C, Cerquetti L, Fallo F, Pilon C, Arnaldi G, Carpinelli G, Stigliano A, et al: Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: Potential therapeutic role of Selective Estrogen Receptor modulators (SERMs) for ACC treatment. J Clin End Metab. 97:E2238–E2250. 2012. View Article : Google Scholar | |
Chimento A, Sirianni R, Casaburi I, Zolea F, Rizza P, Avena P, Malivindi R, De Luca A, Campana C, Martire E, et al: GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget. 6:19190–19203. 2015. View Article : Google Scholar : PubMed/NCBI | |
Giguère V, Yang N, Segui P and Evans RM: Identification of a new class of steroid hormone receptors. Nature. 331:91–94. 1988. View Article : Google Scholar : PubMed/NCBI | |
Deblois G and Giguère V: Functional and physiological genomics of estrogen-related receptors (ERRs) in health and disease. Biochim Biophys Acta. 1812:1032–1040. 2011. View Article : Google Scholar : PubMed/NCBI | |
Casaburi I, Avena P, De Luca A, Chimento A, Sirianni R, Malivindi R, Rago V, Fiorillo M, Domanico F, Campana C, et al: Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget. 6:25135–25148. 2015. View Article : Google Scholar : PubMed/NCBI | |
Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, Reiners C, Allolio B and Schirbel A: [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 97:914–922. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wood BJ, Abraham J, Hvizda JL, Alexander HR and Fojo T: Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 97:554–560. 2003. View Article : Google Scholar : PubMed/NCBI | |
Cazejust J, De B, aère T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S and Baudin E: Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. J Vasc Interv Radiol. 21:1527–1532. 2010. View Article : Google Scholar : PubMed/NCBI |